Drug Evaluation in Angina Pectoris

Häftad, Engelska, 2012

Del i serien Developments in Cardiovascular Medicine

1 665 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

Although there are many books on angina, few are devoted to the important problem of how to evaluate drug efficacy in angina pectoris.

Produktinformation

Utgivningsdatum:2012-10-08
Mått:178 x 254 x 16 mm
Vikt:540 g
Format:Häftad
Språk:Engelska
Serie:Developments in Cardiovascular Medicine
Antal sidor:262
Förlag:Springer-Verlag New York Inc.
ISBN:9781461361275

Utforska kategorier

Hjärt- och kärlsjukdomar inom Medicin

Innehållsförteckning

I. Pathophysiology, Clinical Presentation, and Prognosis of Angina Pectoris.- 1. Pathophysiology, Clinical Presentation, and Prognosis of Angina Pectoris.- II. Evaluation of the Patient with Angina Pectoris.- 2. Clinical Value of Anginal Symptoms and their Assessment in Drug Trials.- 3. Quality of Life Assessments in Clinical Trials of Angina Pectoris.- 4. Optimizing the Exercise Test for Pharmacological Studies in Patients with Angina Pectoris.- 5. Evaluation of Transient Myocardial Ischemia by Holtet Monitoring.- 6. Radionuclide Methods for the Evaluation of Ventricular Function and Thrombolytic Therapy.- 7. Provocative Testing of Coronary Vasoconstriction.- 8. Pharmacological Investigation Using Invasive Methods.- III. Planning, Conducting, and Evaluating Clinical Trials in Angina Pectoris.- 9. Patient Selection and Definition of Study Endpoints.- 10. Controlling Potential Sources of Bias in Clinical Trials of Antianginal Agents.- 11. Parallel-Group and Crossover Designs for Drug Evaluation in the Various Forms of Angina Pectoris.- 12. Dose-Response Relationships and Combination Studies with Antianginal Agents.- 13. Sample Size and Power of Clinical Trials.- 14. Multicenter Trials: Design and Conduct.- IV. Critical Issues Related to Specific Antianginal Agents.- 15. Experimental Evaluation and Clinical Relevance of Tolerance to Nitrates.- 16. Clinical Evaluation of Beta-blockers in Various Forms of Angina Pectoris.- 17. Efficacy and Safety of Calcium Antagonists as Antianginal Agents.- 18. Effects of Antithrombotic Agents on Mortality and Nonfatal Cardiac Events.- 19. The Challenge of Thrombolytic Therapy in Unstable Angina Pectoris.- V. Regulatory Aspects Related to the Evaluation of New Antianginal Agents.- 20. Comments on the Food and Drug Administration (FDA) Cardiac and Renal Drugs Advisory Committee Recommended Guidelines for the Conduct of Antianginal Drug Trials.- 21. European Communities’ Committee for Proprietary Medicinal Products (CPMP) Working Party on Efficacy of Medicinal Products.